Formoterol hemifumarate

Potent, long-acting agonist specific to β2 (Ki = 7.6 nM), but not β1 (Ki > 2.6 µM), adrenergic receptors in trachea (pD2 = 9.3) over atrium (pD2 = 7.0) .1,2 Reduces adhesion and superoxide anion production in cultured activated eosinophils.3 Reverses cachexia in rats and mice via inhibition of the ATP-ubiquitin-dependent proteolytic system.4 Rescues LPS-induced motor function deficits and nigrostriatal dopamine loss in a rat model of Parkinson’s.5 Clinically useful for respiratory diseases.